BioNotebook: Medivation, Clovis, Arena 4Q updates; Abide/Celgene discovery deal; 3 new IPO filers, 2 other set terms
This article was originally published in Scrip
Executive Summary
Medivation, Clovis Oncology and Arena Pharmaceuticals waited until the end of earnings season to provide fourth quarter financial updates and they took a beating on 28 February, which was a tough day for US biotechnology stocks.